195 related articles for article (PubMed ID: 22102709)
1. Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909.
Liu H; Johnson JL; Koval G; Malnassy G; Sher D; Damon LE; Hsi ED; Bucci DM; Linker CA; Cheson BD; Stock W
Haematologica; 2012 Apr; 97(4):579-85. PubMed ID: 22102709
[TBL] [Abstract][Full Text] [Related]
2. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma.
Pott C; Schrader C; Gesk S; Harder L; Tiemann M; Raff T; Brüggemann M; Ritgen M; Gahn B; Unterhalt M; Dreyling M; Hiddemann W; Siebert R; Dreger P; Kneba M
Blood; 2006 Mar; 107(6):2271-8. PubMed ID: 16332971
[TBL] [Abstract][Full Text] [Related]
3. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study.
Pott C; Hoster E; Delfau-Larue MH; Beldjord K; Böttcher S; Asnafi V; Plonquet A; Siebert R; Callet-Bauchu E; Andersen N; van Dongen JJ; Klapper W; Berger F; Ribrag V; van Hoof AL; Trneny M; Walewski J; Dreger P; Unterhalt M; Hiddemann W; Kneba M; Kluin-Nelemans HC; Hermine O; Macintyre E; Dreyling M
Blood; 2010 Apr; 115(16):3215-23. PubMed ID: 20032498
[TBL] [Abstract][Full Text] [Related]
4. Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
Zoellner AK; Unterhalt M; Stilgenbauer S; Hübel K; Thieblemont C; Metzner B; Topp M; Truemper L; Schmidt C; Bouabdallah K; Krauter J; Lenz G; Dürig J; Vergote V; Schäfer-Eckart K; André M; Kluin-Nelemans HC; van Hoof A; Klapper W; Hiddemann W; Dreyling M; Hoster E;
Lancet Haematol; 2021 Sep; 8(9):e648-e657. PubMed ID: 34450102
[TBL] [Abstract][Full Text] [Related]
5. Molecular response after obinutuzumab plus high-dose cytarabine induction for transplant-eligible patients with untreated mantle cell lymphoma (LyMa-101): a phase 2 trial of the LYSA group.
Le Gouill S; Beldi-Ferchiou A; Alcantara M; Cacheux V; Safar V; Burroni B; Guidez S; Gastinne T; Canioni D; Thieblemont C; Maisonneuve H; Bodet-Milin C; Houot R; Oberic L; Bouabdallah K; Bescond C; Damaj G; Jaccard A; Daguindau N; Moreau A; Tilly H; Ribrag V; Delfau-Larue MH; Hermine O; Macintyre E
Lancet Haematol; 2020 Nov; 7(11):e798-e807. PubMed ID: 32971036
[TBL] [Abstract][Full Text] [Related]
6. Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Cowan AJ; Stevenson PA; Cassaday RD; Graf SA; Fromm JR; Wu D; Holmberg LA; Till BG; Chauncey TR; Smith SD; Philip M; Orozco JJ; Shustov AR; Green DJ; Libby EN; Bensinger WI; Shadman M; Maloney DG; Press OW; Gopal AK
Biol Blood Marrow Transplant; 2016 Feb; 22(2):380-385. PubMed ID: 26348890
[TBL] [Abstract][Full Text] [Related]
7. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years.
Kolstad A; Pedersen LB; Eskelund CW; Husby S; Grønbæk K; Jerkeman M; Laurell A; Räty R; Elonen E; Andersen NS; Brown PD; Kimby E; Bentzen H; Sundström C; Ehinger M; Karjalainen-Lindsberg ML; Delabie J; Ralfkiær E; Fagerli UM; Nilsson-Ehle H; Lauritzsen GF; Kuittinen O; Niemann C; Geisler CH;
Biol Blood Marrow Transplant; 2017 Mar; 23(3):428-435. PubMed ID: 28039078
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical and molecular remissions in patients with mantle cell lymphoma following high-dose therapy and autologous stem cell transplantation.
Metzner B; Müller TH; Gebauer W; Casper J; Kraemer D; Rosien B; Schumann-Binarsch S; Thole R; Köhne CH; Dreyling M; Hoster E; Pott C
Ann Hematol; 2014 May; 93(5):803-10. PubMed ID: 24337447
[TBL] [Abstract][Full Text] [Related]
9. The impact of autologous stem cell transplantation on the prognosis of mantle cell lymphoma: a joint analysis of two prospective studies with 46 patients.
Dreger P; Martin S; Kuse R; Sonnen R; Glass B; Kröger N; Parwaresch R; Kneba M; Schmitz N; Haas R
Hematol J; 2000; 1(2):87-94. PubMed ID: 11920175
[TBL] [Abstract][Full Text] [Related]
10. Addition of high-dose cytarabine to immunochemotherapy before autologous stem-cell transplantation in patients aged 65 years or younger with mantle cell lymphoma (MCL Younger): a randomised, open-label, phase 3 trial of the European Mantle Cell Lymphoma Network.
Hermine O; Hoster E; Walewski J; Bosly A; Stilgenbauer S; Thieblemont C; Szymczyk M; Bouabdallah R; Kneba M; Hallek M; Salles G; Feugier P; Ribrag V; Birkmann J; Forstpointner R; Haioun C; Hänel M; Casasnovas RO; Finke J; Peter N; Bouabdallah K; Sebban C; Fischer T; Dührsen U; Metzner B; Maschmeyer G; Kanz L; Schmidt C; Delarue R; Brousse N; Klapper W; Macintyre E; Delfau-Larue MH; Pott C; Hiddemann W; Unterhalt M; Dreyling M;
Lancet; 2016 Aug; 388(10044):565-75. PubMed ID: 27313086
[TBL] [Abstract][Full Text] [Related]
11. Minimal residual disease monitoring by 8-color flow cytometry in mantle cell lymphoma: an EU-MCL and LYSA study.
Cheminant M; Derrieux C; Touzart A; Schmit S; Grenier A; Trinquand A; Delfau-Larue MH; Lhermitte L; Thieblemont C; Ribrag V; Cheze S; Sanhes L; Jardin F; Lefrère F; Delarue R; Hoster E; Dreyling M; Asnafi V; Hermine O; Macintyre E
Haematologica; 2016 Mar; 101(3):336-45. PubMed ID: 26703963
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy with rituximab following high-dose therapy and autologous stem-cell transplantation for mantle cell lymphoma.
Mangel J; Buckstein R; Imrie K; Spaner D; Crump M; Tompkins K; Reis M; Perez-Ordonez B; Deodhare S; Romans R; Pennell N; Robinson JB; Hewitt K; Richardson P; Lima A; Pavlin P; Berinstein NL
Semin Oncol; 2002 Feb; 29(1 Suppl 2):56-69. PubMed ID: 11842390
[TBL] [Abstract][Full Text] [Related]
13. Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma.
Le Gouill S; Thieblemont C; Oberic L; Moreau A; Bouabdallah K; Dartigeas C; Damaj G; Gastinne T; Ribrag V; Feugier P; Casasnovas O; Zerazhi H; Haioun C; Maisonneuve H; Houot R; Jardin F; Van Den Neste E; Tournilhac O; Le Dû K; Morschhauser F; Cartron G; Fornecker LM; Canioni D; Callanan M; Béné MC; Salles G; Tilly H; Lamy T; Gressin R; Hermine O;
N Engl J Med; 2017 Sep; 377(13):1250-1260. PubMed ID: 28953447
[TBL] [Abstract][Full Text] [Related]
14. The role of targeted treatment in mantle cell lymphoma: is transplant dead or alive?
Dreyling M; Ferrero S;
Haematologica; 2016 Feb; 101(2):104-14. PubMed ID: 26830211
[TBL] [Abstract][Full Text] [Related]
15. Mantle cell lymphoma international prognostic index but not pretransplantation induction regimen predicts survival for patients with mantle-cell lymphoma receiving high-dose therapy and autologous stem-cell transplantation.
Budde LE; Guthrie KA; Till BG; Press OW; Chauncey TR; Pagel JM; Petersdorf SH; Bensinger WI; Holmberg LA; Shustov AR; Green DJ; Maloney DG; Gopal AK
J Clin Oncol; 2011 Aug; 29(22):3023-9. PubMed ID: 21730271
[TBL] [Abstract][Full Text] [Related]
16. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations.
Böttcher S; Ritgen M; Buske S; Gesk S; Klapper W; Hoster E; Hiddemann W; Unterhalt M; Dreyling M; Siebert R; Kneba M; Pott C;
Haematologica; 2008 Apr; 93(4):551-9. PubMed ID: 18379010
[TBL] [Abstract][Full Text] [Related]
18. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).
Gianni AM; Magni M; Martelli M; Di Nicola M; Carlo-Stella C; Pilotti S; Rambaldi A; Cortelazzo S; Patti C; Parvis G; Benedetti F; Capria S; Corradini P; Tarella C; Barbui T
Blood; 2003 Jul; 102(2):749-55. PubMed ID: 12663455
[TBL] [Abstract][Full Text] [Related]
19. Lenalidomide maintenance after autologous haematopoietic stem-cell transplantation in mantle cell lymphoma: results of a Fondazione Italiana Linfomi (FIL) multicentre, randomised, phase 3 trial.
Ladetto M; Cortelazzo S; Ferrero S; Evangelista A; Mian M; Tavarozzi R; Zanni M; Cavallo F; Di Rocco A; Stefoni V; Pagani C; Re A; Chiappella A; Balzarotti M; Zilioli VR; Gomes da Silva M; Arcaini L; Molinari AL; Ballerini F; Ferreri AJM; Puccini B; Benedetti F; Stefani PM; Narni F; Casaroli I; Stelitano C; Ciccone G; Vitolo U; Martelli M
Lancet Haematol; 2021 Jan; 8(1):e34-e44. PubMed ID: 33357480
[TBL] [Abstract][Full Text] [Related]
20. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma.
Andersen NS; Donovan JW; Zuckerman A; Pedersen L; Geisler C; Gribben JG
Exp Hematol; 2002 Jul; 30(7):703-10. PubMed ID: 12135667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]